96
Participants
Start Date
February 5, 2018
Primary Completion Date
November 24, 2020
Study Completion Date
November 21, 2021
PCV13
one dose of PCV13 at D0 (arm A) or two double doses at D0 and D7 (Arm B) or one quadruple dose at D0 (arm C)
PPV23
one dose of PPV23 at M5
Rituximab
375 mg/m2/week for 4 consecutive weeks, at Days 0 ± 2 days, Day 7 ± 2 days, Day 14 ± 2 days and Day 21 ± 2 days, as induction therapy of vasculitis flare, followed by 500 mg-rituximab infusion every 6 months as maintenance therapy, i.e. at Month 6, Month 12 and Month 18
"Pôle de Médecine Interne, Centre de référence Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques Hôpital Cochin, Assistance Publique-Hôpitaux de Paris", Paris
Collaborators (1)
EUCLID Clinical Trial Platform
OTHER
Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
OTHER
CIC 1417 Cochin-Pasteur
OTHER
Groupe Français d'Etude des Vascularites (GFEV)
UNKNOWN
Assistance Publique - Hôpitaux de Paris
OTHER